FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1828-1830 June 23, 1994 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by O'Brien, S.

To the Editor: O'Brien et al. (Feb. 3 issue)¹ reported a low rate of remission after 2-chlorodeoxyadenosine therapy among patients with chronic lymphocytic leukemia refractory to fludarabine. However, 57 percent of the patients had a decrease in the lymphocyte count of 50 percent or more. The study confirmed that patients who have already received extensive therapy are at high risk for thrombocytopenia when treated with 2-chlorodeoxyadenosine. In our experience, thrombocytopenia due to 2-chlorodeoxyadenosine is no more common among patients who have received fludarabine than among patients who have received other therapy,² and it may also develop in previously untreated patients³. . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.